Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.38 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | KIF20A | O95235 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189380 | 1.00 | NQO2 (0.47) | NQO2PTGS1PKML3MBTL1HPGD | |
| SCHEMBL4189377 | 1.00 | NQO2 (0.47) | NQO2PTGS1PKML3MBTL1HPGD | |
| SCHEMBL4192011 | 0.91 | NQO2 (0.53) | NQO2PTGS1PKMHPGDEGFR | |
| SCHEMBL4192017 | 0.91 | NQO2 (0.53) | NQO2PTGS1PKMHPGDEGFR | |
| SCHEMBL4192014 | 0.91 | NQO2 (0.53) | NQO2PTGS1PKMHPGDEGFR | |
| SCHEMBL4168075 | 0.89 | PKM (0.54) | PKML3MBTL1HPGDEGFRMEN1 | |
| SCHEMBL4184666 | 0.89 | ALDH1A1 (0.46) | NQO2PKML3MBTL1HPGDEGFR | |
| SCHEMBL4184669 | 0.89 | ALDH1A1 (0.46) | NQO2PKML3MBTL1HPGDEGFR | |
| SCHEMBL4184673 | 0.89 | ALDH1A1 (0.46) | NQO2PKML3MBTL1HPGDEGFR | |
| SCHEMBL4168077 | 0.89 | PKM (0.54) | PKML3MBTL1HPGDEGFRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | ARSA, STS, SULT2A1 | NQO2 1049/4885PTGS1 741/4885PKM 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.